Episode 26: Bigger Models Won't Save Biomanufacturing

<p>We sit down with <a href="https://www.linkedin.com/in/shawn-manchester-04931289/">Shawn Manchester</a>, CEO of TripleBar, whose path from yeast DNA repair to metabolic engineering at MIT to biomanufacturing AI gave him a front-row seat to one of biotech&#39;s most underappreciated problems. </p><p>Everyone funds discovery. Nobody funds manufacturing. And yet a molecule that can&#39;t be made reliably and cheaply at scale never reaches a patient. Shawn makes the case that biomanufacturing is where the real bottleneck lives, and why it&#39;s finally getting the AI attention it deserves. It&#39;s a refreshingly grounded conversation about what biological AI actually requires to work.</p>